Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 04/27/26
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPSZacks Investment Research • 04/27/26
Will Lower Gardasil Sales Hurt MRK's Vaccines Sales in Q1 Earnings?Zacks Investment Research • 04/24/26
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.Business Wire • 04/24/26
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/23/26
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer StudyZacks Investment Research • 04/22/26
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise TransformationPRNewsWire • 04/22/26
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources sayReuters • 04/22/26
MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority TagZacks Investment Research • 04/21/26
Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?Zacks Investment Research • 04/21/26
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage studyReuters • 04/21/26
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)Business Wire • 04/21/26
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder CancerBusiness Wire • 04/20/26
European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV SeasonBusiness Wire • 04/17/26
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung CancerZacks Investment Research • 04/14/26